{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T17:23:43Z","timestamp":1790011423488,"version":"4.0.1"},"reference-count":36,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100021177","name":"Shenzhen Bay Laboratory","doi-asserted-by":"publisher","award":["21310051"],"award-info":[{"award-number":["21310051"]}],"id":[{"id":"10.13039\/501100021177","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bioorganic Chemistry"],"published-print":{"date-parts":[[2025,1]]},"DOI":"10.1016\/j.bioorg.2024.108080","type":"journal-article","created":{"date-parts":[[2024,12,20]],"date-time":"2024-12-20T13:00:27Z","timestamp":1734699627000},"page":"108080","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"special_numbering":"C","title":["Discovery of a novel CDK4\/6 and HDAC dual-targeting agent for the treatment of hepatocellular carcinoma"],"prefix":"10.1016","volume":"154","author":[{"given":"Zizhou","family":"Niu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhichao","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guoxiang","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanping","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weibin","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fakai","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tingting","family":"Fan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaifei","family":"Shu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiuhua","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mengmeng","family":"Dai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cailian","family":"Zhi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cheng","family":"Qiu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yilin","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lihong","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Funian","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yijie","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tingbiao","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zijian","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yue","family":"Hao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuyang","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.bioorg.2024.108080_b0005","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1038\/s41575-022-00704-9","article-title":"Evolving therapeutic landscape of advanced hepatocellular carcinoma","volume":"20","author":"Yang","year":"2023","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"issue":"10360","key":"10.1016\/j.bioorg.2024.108080_b0010","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1016\/S0140-6736(22)01200-4","article-title":"Hepatocellular carcinoma","volume":"400","author":"Vogel","year":"2022","journal-title":"Lancet"},{"issue":"9","key":"10.1016\/j.bioorg.2024.108080_b0015","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2023-007366","article-title":"Lenvatinib plus anti-PD-1 antibodies as conversion therapy for patients with unresectable intermediate-advanced hepatocellular carcinoma: a single-arm, phase II trial","volume":"11","author":"Zhang","year":"2023","journal-title":"J. Immunother Cancer"},{"issue":"15","key":"10.1016\/j.bioorg.2024.108080_b0020","doi-asserted-by":"crossref","first-page":"10791","DOI":"10.1021\/acs.jmedchem.3c01008","article-title":"Discovery of Novel 1,2,3,4-Tetrahydrobenzofuro[2,3-c]pyridine Histone Deacetylase Inhibitors for Efficient Treatment of Hepatocellular Carcinoma","volume":"66","author":"Lai","year":"2023","journal-title":"J. Med. Chem."},{"issue":"1","key":"10.1016\/j.bioorg.2024.108080_b0025","first-page":"7","article-title":"Cancer statistics, 2022","volume":"72","author":"Siegel","year":"2022","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.bioorg.2024.108080_b0030","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2020.104686","article-title":"A unique CDK4\/6 inhibitor: Current and future therapeutic strategies of abemaciclib","volume":"156","author":"Chong","year":"2020","journal-title":"Pharmacol. Res."},{"issue":"9","key":"10.1016\/j.bioorg.2024.108080_b0035","doi-asserted-by":"crossref","first-page":"6390","DOI":"10.1021\/acs.jmedchem.1c02064","article-title":"From Structure Modification to Drug Launch: A Systematic Review of the Ongoing Development of Cyclin-Dependent Kinase Inhibitors for Multiple Cancer Therapy","volume":"65","author":"Shi","year":"2022","journal-title":"J. Med. Chem."},{"issue":"2","key":"10.1016\/j.bioorg.2024.108080_b0040","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1038\/nrc.2016.138","article-title":"Cell cycle proteins as promising targets in cancer therapy","volume":"17","author":"Otto","year":"2017","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.bioorg.2024.108080_b0045","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2020.112073","article-title":"Discovery of novel cyclin-dependent kinase (CDK) and histone deacetylase (HDAC) dual inhibitors with potent invitro and invivo anticancer activity","volume":"189","author":"Cheng","year":"2020","journal-title":"Eur. J. Med. Chem."},{"issue":"6577","key":"10.1016\/j.bioorg.2024.108080_b0050","doi-asserted-by":"crossref","DOI":"10.1126\/science.abc1495","article-title":"CDK4 and CDK6 kinases: From basic science to cancer therapy","volume":"375","author":"Fassl","year":"2022","journal-title":"Science"},{"issue":"10","key":"10.1016\/j.bioorg.2024.108080_b0055","doi-asserted-by":"crossref","first-page":"2273","DOI":"10.1158\/1535-7163.MCT-16-0300","article-title":"Spectrum and Degree of CDK Drug Interactions Predicts Clinical Performance","volume":"15","author":"Chen","year":"2016","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.bioorg.2024.108080_b0060","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1016\/j.ejmech.2019.01.003","article-title":"Recent development of CDK inhibitors: An overview of CDK\/inhibitor co-crystal structures","volume":"164","author":"Cheng","year":"2019","journal-title":"Eur. J. Med. Chem."},{"issue":"5","key":"10.1016\/j.bioorg.2024.108080_b0065","doi-asserted-by":"crossref","first-page":"R77","DOI":"10.1186\/bcr2419","article-title":"PD 0332991, a selective cyclin D kinase 4\/6 inhibitor, preferentially inhibits proliferation of luminal estrogen receptor-positive human breast cancer cell lines in vitro","volume":"11","author":"Finn","year":"2009","journal-title":"Breast Cancer Res."},{"issue":"7","key":"10.1016\/j.bioorg.2024.108080_b0070","doi-asserted-by":"crossref","first-page":"1286","DOI":"10.1136\/gutjnl-2016-312268","article-title":"Palbociclib (PD-0332991), a selective CDK4\/6 inhibitor, restricts tumour growth in preclinical models of hepatocellular carcinoma","volume":"66","author":"Bollard","year":"2017","journal-title":"Gut"},{"key":"10.1016\/j.bioorg.2024.108080_b0075","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2021.113453","article-title":"Design, synthesis, and biological evaluation of novel dual inhibitors targeting lysine specific demethylase 1 (LSD1) and histone deacetylases (HDAC) for treatment of gastric cancer","volume":"220","author":"Duan","year":"2021","journal-title":"Eur. J. Med. Chem."},{"issue":"9","key":"10.1016\/j.bioorg.2024.108080_b0080","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1038\/nrd4360","article-title":"Histone deacetylases and their inhibitors in cancer, neurological diseases and immune disorders","volume":"13","author":"Falkenberg","year":"2014","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.bioorg.2024.108080_b0085","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1016\/j.ejmech.2016.05.047","article-title":"Inside HDACs with more selective HDAC inhibitors","volume":"121","author":"Roche","year":"2016","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bioorg.2024.108080_b0090","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2020.112954","article-title":"Small-molecule inhibitors of breast cancer-related targets: Potential therapeutic agents for breast cancer","volume":"210","author":"Liu","year":"2021","journal-title":"Eur. J. Med. Chem."},{"issue":"7","key":"10.1016\/j.bioorg.2024.108080_b0095","doi-asserted-by":"crossref","first-page":"3166","DOI":"10.1021\/acs.jmedchem.8b00209","article-title":"Discovery of N1-(4-((7-Cyclopentyl-6-(dimethylcarbamoyl)-7H-pyrrolo[2,3-d]pyrimidin-2-yl)amino)phenyl)-N8-hydroxyoctanediamide as a Novel Inhibitor Targeting Cyclin-dependent Kinase 4\/9 (CDK4\/9) and Histone Deacetlyase1 (HDAC1) against Malignant Cancer","volume":"61","author":"Li","year":"2018","journal-title":"J. Med. Chem."},{"issue":"3","key":"10.1016\/j.bioorg.2024.108080_b0100","first-page":"901","article-title":"Mechanisms of the CDK4\/6 inhibitor palbociclib (PD 0332991) and its future application in cancer treatment (Review)","volume":"39","author":"Liu","year":"2018","journal-title":"Oncol. Rep."},{"issue":"8","key":"10.1016\/j.bioorg.2024.108080_b0105","doi-asserted-by":"crossref","first-page":"4256","DOI":"10.1021\/acs.jmedchem.0c00193","article-title":"Design, Synthesis, and Biological Evaluation of Quinazolin-4-one-Based Hydroxamic Acids as Dual PI3K\/HDAC Inhibitors","volume":"63","author":"Thakur","year":"2020","journal-title":"J. Med. Chem."},{"issue":"3","key":"10.1016\/j.bioorg.2024.108080_b0110","doi-asserted-by":"crossref","first-page":"1578","DOI":"10.1002\/med.21769","article-title":"How selective are clinical CDK4\/6 inhibitors?","volume":"41","author":"Hendrychov\u00e1","year":"2021","journal-title":"Med. Res. Rev."},{"key":"10.1016\/j.bioorg.2024.108080_b0115","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2020.112239","article-title":"Discovery of a novel series of imidazo[1\u2032,2\u2019:1,6]pyrido[2,3-d]pyrimidin derivatives as potent cyclin-dependent kinase 4\/6 inhibitors","volume":"193","author":"Shi","year":"2020","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bioorg.2024.108080_b0120","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2021.113432","article-title":"Discovery of a novel covalent CDK4\/6 inhibitor based on palbociclib scaffold","volume":"219","author":"Shan","year":"2021","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bioorg.2024.108080_b0125","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.2147\/DDDT.S351049","article-title":"Design, Synthesis, and Biological Evaluation of 2-Anilino-4-Triazolpyrimidine Derivatives as CDK4\/HDACs Inhibitors","volume":"16","author":"Wang","year":"2022","journal-title":"Drug Des. Devel. Ther."},{"issue":"20","key":"10.1016\/j.bioorg.2024.108080_b0130","doi-asserted-by":"crossref","first-page":"15280","DOI":"10.1021\/acs.jmedchem.1c01311","article-title":"Indirubin Derivatives as Dual Inhibitors Targeting Cyclin-Dependent Kinase and Histone Deacetylase for Treating Cancer","volume":"64","author":"Cao","year":"2021","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2024.108080_b0135","doi-asserted-by":"crossref","unstructured":"I. Chowdhury, B. Tharakan, G.K. Bhat, Caspases \u2014 An update. Comp. Biochem. Physiol. B Biochem. Mol. Biol. 151 (1) (2008) 10-27, 10.1016\/j.cbpb.2008.05.010.","DOI":"10.1016\/j.cbpb.2008.05.010"},{"key":"10.1016\/j.bioorg.2024.108080_b0140","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2022.114402","article-title":"Design, synthesis and antitumor evaluation of novel 1H-indole-2-carboxylic acid derivatives targeting 14-3-3\u03b7 protein","volume":"238","author":"Gao","year":"2022","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bioorg.2024.108080_b0145","doi-asserted-by":"crossref","unstructured":"A. Ray Chaudhuri, Y. Hashimoto, R. Herrador, K.J. Neelsen, D. Fachinetti, R. Bermejo, A. Cocito, V. Costanzo, M. Lopes, Topoisomerase I poisoning results in PARP-mediated replication fork reversal. Nat. Struct. Mol. Biol. 19 (4) (2012) 417-423, 10.1038\/nsmb.2258.","DOI":"10.1038\/nsmb.2258"},{"issue":"9","key":"10.1016\/j.bioorg.2024.108080_b0150","doi-asserted-by":"crossref","first-page":"1506","DOI":"10.1128\/MCB.01206-14","article-title":"Brk\/Protein Tyrosine Kinase 6 Phosphorylates p27KIP1, Regulating the Activity of Cyclin D\u2013Cyclin-Dependent Kinase 4","volume":"35","author":"Patel","year":"2015","journal-title":"Mol. Cell Biol."},{"issue":"4","key":"10.1016\/j.bioorg.2024.108080_b0155","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1128\/MCB.00898-08","article-title":"p27Kip1 Inhibits Cyclin D-Cyclin-Dependent Kinase 4 by Two Independent Modes","volume":"29","author":"Ray","year":"2009","journal-title":"Mol. Cell Biol."},{"issue":"12","key":"10.1016\/j.bioorg.2024.108080_b0160","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1007\/s00109-016-1475-3","article-title":"Cyclin D1, cancer progression, and opportunities in cancer treatment","volume":"94","author":"Qie","year":"2016","journal-title":"J. Mol. Med."},{"issue":"9","key":"10.1016\/j.bioorg.2024.108080_b0165","doi-asserted-by":"crossref","first-page":"7539","DOI":"10.1021\/acs.jmedchem.4c00373","article-title":"Science review: apoptosis in acute lung injury","volume":"67","author":"Khan","year":"2024","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2024.108080_b0170","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2021.105026","article-title":"Discovery of the PARP (poly ADP-ribose polymerase) inhibitor 2-(1-(4,4-difluorocyclohexyl)piperidin-4-yl)-1H-benzo[d]imidazole-4-carboxamide for the treatment of cancer","volume":"114","author":"Tang","year":"2021","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.bioorg.2024.108080_b0175","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2023.107078","article-title":"Design, synthesis, and evaluation of VHL-based EZH2 degraders for breast cancer","volume":"143","author":"Xiao","year":"2024","journal-title":"Bioorg. Chem."},{"issue":"9","key":"10.1016\/j.bioorg.2024.108080_b0180","doi-asserted-by":"crossref","first-page":"1516","DOI":"10.1021\/acsmedchemlett.4c00256","article-title":"Design and Synthesis of c-Met and HDAC Dual Inhibitors for the Treatment of Breast Cancer","volume":"15","author":"Wang","year":"2024","journal-title":"ACS Med. Chem. Lett."}],"container-title":["Bioorganic Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0045206824009854?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0045206824009854?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T11:59:17Z","timestamp":1777463957000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0045206824009854"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1]]},"references-count":36,"alternative-id":["S0045206824009854"],"URL":"https:\/\/doi.org\/10.1016\/j.bioorg.2024.108080","relation":{},"ISSN":["0045-2068"],"issn-type":[{"value":"0045-2068","type":"print"}],"subject":[],"published":{"date-parts":[[2025,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Discovery of a novel CDK4\/6 and HDAC dual-targeting agent for the treatment of hepatocellular carcinoma","name":"articletitle","label":"Article Title"},{"value":"Bioorganic Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bioorg.2024.108080","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"108080"}}